换一批
换一批Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
作者：
Reid W,Merryman [1]
;
Robert A,Redd [2]
;
Taiga,Nishihori [3]
;
Julio,Chavez [3]
;
Yago,Nieto [4]
;
Justin M,Darrah [5]
;
Uttam,Rao [6]
;
Michael T,Byrne [7]
;
David A,Bond [7]
;
Kami J,Maddocks [8]
;
Michael A,Spinner [8]
;
Ranjana H,Advani [9]
;
Hatcher J,Ballard [9]
;
Jakub,Svoboda [10]
;
Anurag K,Singh [10]
;
Joseph P,McGuirk [11]
;
Dipenkumar,Modi [11]
;
Radhakrishnan,Ramchandren [12]
;
Jason,Romancik [13]
;
Jonathon B,Cohen [14]
;
Matthew J,Frigault [14]
;
Yi-Bin,Chen [15]
;
Anthony V,Serritella [15]
;
Justine,Kline [16]
;
Stephen,Ansell [16]
;
Sunita,Nathan [17]
;
Maryam,Rahimian [18]
;
Robin M,Joyce [19]
;
Mansi,Shah [19]
;
Kevin A,David [20]
;
Steven,Park [20]
;
Anne W,Beaven [21]
;
Alma,Habib [22]
;
Veronika,Bachanova [23]
;
Shazia,Nakhoda [23]
;
Nadia,Khan [24]
;
Ryan C,Lynch [24]
;
Stephen D,Smith [25]
;
Vincent T,Ho [25]
;
Ann,LaCasce [1]
;
Philippe,Armand [1]
;
Alex F,Herrera [1]
作者单位：
Division of Hematologic Malignancies and.
[1]
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.
[2]
Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL.
[3]
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.
[4]
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
[5]
Cedars-Sinai Medical Center, Los Angeles, CA.
[6]
Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
[7]
Division of Hematology, Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University Hospital, Columbus, OH.
[8]
Division of Oncology, Department of Medicine, Stanford University, Stanford, CA.
[9]
Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.
[10]
Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS.
[11]
Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI.
[12]
Division of Hematology/Oncology, University of Tennessee School of Medicine, Knoxville, TN.
[13]
Department of Hematology and Medical Oncology, Emory University-Winship Cancer Institute, Atlanta, GA.
[14]
Bone Marrow Transplantation Program, Massachusetts General Hospital, Boston, MA.
[15]
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.
[16]
Division of Hematology, Mayo Clinic, Rochester, MN.
[17]
Section of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, Chicago, IL.
[18]
Beth Israel Deaconess Medical Center, Boston, MA.
[19]
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
[20]
Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC.
[21]
Division of Hematology, University of North Carolina, Chapel Hill, NC.
[22]
Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN.
[23]
Division of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA; and.
[24]
University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA.
[25]
主题词
抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);造血干细胞移植(Hematopoietic Stem Cell Transplantation);霍奇金病(Hodgkin Disease);人类(Humans);肿瘤复发, 局部(Neoplasm Recurrence, Local);回顾性研究(Retrospective Studies);移植, 自体(Transplantation, Autologous)
DOI
10.1182/bloodadvances.2020003556
PMID
33710337
发布时间
2022-09-24
- 浏览0
Blood advances
Blood advances
2021年5卷6期
1648-1659页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
